Felzartamab（Cat No.:I042105）is an investigational monoclonal antibody designed to target and inhibit the activity of the protein FcgRIIB, a receptor involved in immune regulation. It is being studied primarily for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE). By blocking FcgRIIB, felzartamab aims to enhance the immune system’s ability to fight disease and reduce harmful inflammation. Its potential to modulate immune responses has drawn attention for conditions where the immune system mistakenly attacks the body’s own tissues, though further clinical trials are required to confirm its efficacy and safety.
